CORGENTECH TO MERGE WITH ALGORX IN SHARE EXCHANGE

Drug developer Corgentech Inc. (CGTK.O: Quote, Profile, Research) said on Monday it agreed to merge with privately held AlgoRx Pharmaceuticals Inc. in a share exchange deal. The combined company will have four products in its pipeline, including Corgentech's experimental treatment for eczema, which is in Phase I/II trials, and an experimental topical local anesthesia being developed by AlgoRx that is in Phase III trials.

Reuters (http://today.reuters.com/investing/financeArticle.aspx?type=mergersNews&storyID=2005-09-26T120621Z_01_BNG106024_RTRIDST_0_HEALTH-ALGORX-CORGENTECH-UPDATE-1.XML)